Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers
Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers
复制标题
DOI：
10.1093/annonc/mdq678
复制
发表时间：
2011-08-01
影响因子：
50.5
通讯作者：
Lee, K. S.
中科院分区：
文献类型：
--
作者：
Park, S.;Koo, J. S.;Lee, K. S.
背景：本研究的目的是评估雄激素受体（AR）在乳腺癌中的意义。患者和方法：我们研究了1999年至2005年间931例患者的组织微阵列免疫组织化学AR表达，并使用单/多变量分析分析了人口统计学和结果。结果：AR在58.1%的患者中表达。AR与诊断年龄较大、肿瘤体积较小、分化良好、激素受体阳性程度较高、非三阴性乳腺癌（non- tnbc）、低增殖指数显著相关。在雌激素受体（ER）阴性肿瘤中，AR与人表皮生长因子受体2型（HER2）过表达明显相关。在平均72.7个月的随访中，AR与er阳性肿瘤的生存率呈正相关，而与er阴性肿瘤的生存率无关。在Cox模型中，AR是er阳性癌症无病生存的独立预后因素。有趣的是，HER2阳性的分子大泌腺肿瘤（ER阴性和AR阳性）表现出预后较差的趋势，但AR对TNBC患者的生存没有影响。结论：AR与乳腺癌的有利特征显著相关，并且与er阳性而非er阴性肿瘤的更好预后相关。这些结果表明，AR可能是雌激素受体阳性癌症中内分泌反应性的额外标记物，也可能是雌激素受体阴性肿瘤的治疗靶点。
Background: The objective of the study was to evaluate the implications of androgen receptor (AR) in breast cancers.Patients and methods: We investigated immunohistochemical AR expression from the tissue microarrays of 931 patients between 1999 and 2005, and analyzed demographics and outcomes using uni-/multivariate analyses. Tumors with 10% nuclear-stained cells were considered positive for AR.Results: AR was expressed in 58.1% of patients. AR was significantly related to older age at diagnosis, smaller size, well-differentiated tumors, higher positivity of hormone receptors, non-triple-negative breast cancers (non-TNBCs), and lower proliferative index. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with human epidermal growth factor receptor type 2 (HER2) overexpression. With a mean follow-up of 72.7 months, AR was positively related to survival in ER-positive but not in ER-negative tumors. In Cox's models, AR was an independent prognostic factor for disease-free survival in ER-positive cancers. Interestingly, molecular apocrine tumors (ER negative and AR positive) with HER2 positive status showed trends of poorer outcome, but AR had no impact on survival in patients with TNBC.Conclusions: AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.